MedTrace Logo

CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL).

NCT06078306 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2024-04-22

No results posted yet for this study

Summary

Clinical trial for the safety and efficacy of induction chemotherapy with VA regime and bridging CD19CD22 CAR-T therapy in adult patients with newly diagnosed high-risk and Ph- B-ALL

Conditions

  • B Acute Lymphoblastic Leukemia
  • Ph-Negative ALL
  • High Risk Acute Lymphoblastic Leukemia

Interventions

DRUG

Azacitidine Injection

Azacitidine Injection 75mg/square meter/day, day1-7, subcutaneous injection

DRUG

Venetoclax

Venetoclax 100mg day 1, 200mg day 2, 400mg d3-d21, oral

DRUG

CD19CD22 CAR-T

After induction chemotherapy with Azacitidine+Venetoclax, each subject receives CD19CD22 CAR-T cells by intravenous infusion

Sponsors & Collaborators

  • The First Affiliated Hospital of Soochow University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-20
Primary Completion
2024-09-10
Completion
2025-09-10

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06078306 on ClinicalTrials.gov